These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 22362559)
1. Anticoagulation after subcutaneous enoxaparin is time sensitive in STEMI patients treated with tenecteplase. Welsh RC; Westerhout CM; Buller CE; O'Neill B; Gordon P; Armstrong PW J Thromb Thrombolysis; 2012 Jul; 34(1):126-31. PubMed ID: 22362559 [TBL] [Abstract][Full Text] [Related]
2. A novel enoxaparin regime for ST elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: a WEST sub-study. Welsh RC; Gordon P; Westerhout CM; Buller CE; O'Neill B; Armstrong PW Catheter Cardiovasc Interv; 2007 Sep; 70(3):341-8. PubMed ID: 17295333 [TBL] [Abstract][Full Text] [Related]
3. A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention. Choussat R; Montalescot G; Collet JP; Vicaut E; Ankri A; Gallois V; Drobinski G; Sotirov I; Thomas D J Am Coll Cardiol; 2002 Dec; 40(11):1943-50. PubMed ID: 12475453 [TBL] [Abstract][Full Text] [Related]
4. Subcutaneous enoxaparin following thrombolysis and intravenous unfractionated heparin in ST-elevation acute myocardial infarction: safety and efficacy of low vs full dose. Rubboli A; Gatti C; Spinolo L; Parollo R; Spitali G; Maresta A Minerva Cardioangiol; 2006 Feb; 54(1):131-7. PubMed ID: 16467747 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators Lancet; 2001 Aug; 358(9282):605-13. PubMed ID: 11530146 [TBL] [Abstract][Full Text] [Related]
6. Facilitated percutaneous coronary intervention for acute ST-segment elevation myocardial infarction: results from the prematurely terminated ADdressing the Value of facilitated ANgioplasty after Combination therapy or Eptifibatide monotherapy in acute Myocardial Infarction (ADVANCE MI) trial. ADVANCE MI Investigators Am Heart J; 2005 Jul; 150(1):116-22. PubMed ID: 16084157 [TBL] [Abstract][Full Text] [Related]
9. Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated heparin, enoxaparin, or abciximab. Dubois CL; Belmans A; Granger CB; Armstrong PW; Wallentin L; Fioretti PM; López-Sendón JL; Verheugt FW; Meyer J; Van de Werf F; J Am Coll Cardiol; 2003 Oct; 42(7):1178-85. PubMed ID: 14522476 [TBL] [Abstract][Full Text] [Related]
10. Primary percutaneous coronary intervention for ST-elevation myocardial infarction using an intravenous and subcutaneous enoxaparin low molecular weight heparin regimen. Khoobiar S; Mejevoi N; Kaid K; Boiangiu C; Setty S; Tanwir A; Khalid K; Cohen M J Thromb Thrombolysis; 2008 Oct; 26(2):85-90. PubMed ID: 18636227 [TBL] [Abstract][Full Text] [Related]
11. A comparison of pharmacologic therapy with/without timely coronary intervention vs. primary percutaneous intervention early after ST-elevation myocardial infarction: the WEST (Which Early ST-elevation myocardial infarction Therapy) study. Armstrong PW; Eur Heart J; 2006 Jul; 27(13):1530-8. PubMed ID: 16757491 [TBL] [Abstract][Full Text] [Related]
12. Degree of anticoagulation after one subcutaneous and one subsequent intravenous booster dose of enoxaparin: implications for patients with acute coronary syndromes undergoing early percutaneous coronary intervention. Levine GN; Ferrando T J Thromb Thrombolysis; 2004 Jun; 17(3):167-71. PubMed ID: 15353913 [TBL] [Abstract][Full Text] [Related]
13. Safety and Efficacy of a Pharmacoinvasive Strategy in ST-Segment Elevation Myocardial Infarction: A Patient Population Study Comparing a Pharmacoinvasive Strategy With a Primary Percutaneous Coronary Intervention Strategy Within a Regional System. Rashid MK; Guron N; Bernick J; Wells GA; Blondeau M; Chong AY; Dick A; Froeschl MPV; Glover CA; Hibbert B; Labinaz M; Marquis JF; Osborne C; So DY; Le May MR JACC Cardiovasc Interv; 2016 Oct; 9(19):2014-2020. PubMed ID: 27712737 [TBL] [Abstract][Full Text] [Related]
14. Transfer for urgent percutaneous coronary intervention early after thrombolysis for ST-elevation myocardial infarction: the TRANSFER-AMI pilot feasibility study. Cantor WJ; Burnstein J; Choi R; Heffernan M; Dzavik V; Lazzam C; Duic M; Fitchett D; Tan M; Wawrzyniak J; Kassam S; Dhingra S; Morrison LJ; Langer A; Goodman SG Can J Cardiol; 2006 Nov; 22(13):1121-6. PubMed ID: 17102829 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: one-year follow-up results of the Assessment of the Safety of a New Thrombolytic-3 (ASSENT-3) randomized trial in acute myocardial infarction. Sinnaeve PR; Alexander JH; Bogaerts K; Belmans A; Wallentin L; Armstrong P; Adgey JA; Tendera M; Diaz R; Soares-Piegas L; Vahanian A; Granger CB; Van De Werf FJ Am Heart J; 2004 Jun; 147(6):993-8. PubMed ID: 15199346 [TBL] [Abstract][Full Text] [Related]
16. Prehospital administration of enoxaparin before primary angioplasty for ST-elevation acute myocardial infarction. Labèque JN; Jaïs C; Dubos O; Denard M; Berhouet M; Leroux L; Laplace G; Vergnes C; Pradeau C; Thicoïpe M; Dos Santos P; Coste P Catheter Cardiovasc Interv; 2006 Feb; 67(2):207-13. PubMed ID: 16416473 [TBL] [Abstract][Full Text] [Related]
17. Multicenter randomized trial of facilitated percutaneous coronary intervention with low-dose tenecteplase in patients with acute myocardial infarction: the Athens PCI trial. Kanakakis J; Nanas JN; Tsagalou EP; Maroulidis GD; Drakos SG; Ntalianis AS; Tzoumele P; Skoumbourdis E; Charbis P; Rokas S; Anastasiou-Nana M Catheter Cardiovasc Interv; 2009 Sep; 74(3):398-405. PubMed ID: 19360864 [TBL] [Abstract][Full Text] [Related]
18. Reliable anticoagulation with enoxaparin in patients undergoing percutaneous coronary intervention: The pharmacokinetics of enoxaparin in PCI (PEPCI) study. Martin JL; Fry ET; Sanderink GJ; Atherley TH; Guimart CM; Chevalier PJ; Ozoux ML; Pensyl CE; Bigonzi F Catheter Cardiovasc Interv; 2004 Feb; 61(2):163-70. PubMed ID: 14755805 [TBL] [Abstract][Full Text] [Related]
19. Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial. Gibson CM; Murphy SA; Montalescot G; Morrow DA; Ardissino D; Cohen M; Gulba DC; Kracoff OH; Lewis BS; Roguin N; Antman EM; Braunwald E; J Am Coll Cardiol; 2007 Jun; 49(23):2238-46. PubMed ID: 17560287 [TBL] [Abstract][Full Text] [Related]
20. Streptokinase and enoxaparin as an alternative to fibrin-specific lytic-based regimens: an ExTRACT-TIMI 25 analysis. Giraldez RR; Wiviott SD; Nicolau JC; Mohanavelu S; Morrow DA; Antman EM; Giugliano RP Drugs; 2009 Jul; 69(11):1433-43. PubMed ID: 19634922 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]